<p>Ardelyx Inc. reported preliminary unaudited U.S. net product sales revenue for the fourth quarter (Q4) ended December 31, 2025, with IBSRELA generating approximately USD 87 million and XPHOZAH approximately USD 28 million. For the full year (FY) 2025, U.S. net product sales revenue reached approximately USD 274 million for IBSRELA and approximately USD 104 million for XPHOZAH. As of December 31, 2025, Ardelyx Inc. had cash, cash equivalents, and short-term investments totaling approximately USD 265 million. The company noted these figures are preliminary and may be subject to adjustment following the completion of audited financial statements. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardelyx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437402-26-000003), on January 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

Ardelyx reports FY 2025 IBSRELA net product sales revenue of USD 274 million and XPHOZAH net product sales revenue of USD 104 million